Article ; Online: Is it safe to withdraw low-dose glucocorticoids in SLE patients in remission?
2023 Volume 23, Issue 1, Page(s) 103446
Abstract: Glucocorticoids (GCs) remain a cornerstone of the treatment of Systemic Lupus Erythematosus (SLE). Numerous studies have emphasized the risk of damage accrual in SLE patient treated with GC, but currently, it is not possible to dissociate favorable and ... ...
| Abstract | Glucocorticoids (GCs) remain a cornerstone of the treatment of Systemic Lupus Erythematosus (SLE). Numerous studies have emphasized the risk of damage accrual in SLE patient treated with GC, but currently, it is not possible to dissociate favorable and undesirable effects of GCs because their underlying mechanisms are entangled at the molecular level. Here, we review whether available data suggest that it is possible, feasible and desirable to taper and discontinue GC treatment in SLE. The main potential concern with GC withdrawal is the risk of SLE flare, which is strongly associated with increased organ damage, mortality, healthcare costs, decreased quality of life and work productivity. While most studies have assumed the cut off point for low doses (e.g. 7.5/mg/d) as the limit for safety, it is still controversial whether lower doses may influence damage accrual long-term. Also, a recent randomized trial has shown that a daily dose of 5 mg of prednisone in SLE patients in short-term remission can prevent up to 50-75% of flares, with an acceptable safety profile. However, this treatment is not mandatory for all patients. Yet, several observational studies highlight that discontinuation of GC is associated with lower damage accrual. Currently, we do not have a reliable method to identify patients who may require long-term low-dose GC. Therefore, further research is needed to identify a subgroup at high risk of relapse who would benefit from continuing prednisone. In the meantime, when considering the discontinuation of very low-dose prednisone, the decision must be individualized, as HCQ and conventional immunosuppressive agents are not without risk of side effects. |
|---|---|
| MeSH term(s) | Humans ; Glucocorticoids/adverse effects ; Prednisone/therapeutic use ; Quality of Life ; Lupus Erythematosus, Systemic/complications ; Immunosuppressive Agents/therapeutic use ; Severity of Illness Index |
| Chemical Substances | Glucocorticoids ; Prednisone (VB0R961HZT) ; Immunosuppressive Agents |
| Language | English |
| Publishing date | 2023-09-06 |
| Publishing country | Netherlands |
| Document type | Journal Article ; Review |
| ZDB-ID | 2144145-5 |
| ISSN | 1873-0183 ; 1568-9972 |
| ISSN (online) | 1873-0183 |
| ISSN | 1568-9972 |
| DOI | 10.1016/j.autrev.2023.103446 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 5913: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.